Comparing standard and intensive HIV treatment for early infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effects of standard Highly Active Antiretroviral Therapy (HAART) versus mega-HAART in individuals with acute HIV infection. Participants enrolled in the SEARCH 010 protocol will be randomized to receive one of the two treatment regimens. The study will monitor immunological and virological outcomes, including HIV-1 plasma viral RNA levels and CD4 counts, as well as track adherence and any adverse events related to the treatments. The goal is to determine which treatment approach yields better health outcomes during the acute phase of HIV infection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old
2. Enrolled in the SEARCH 010 or 013 protocols with documentation of acute or chronic protocol defined HIV-1 infection and chooses to initiate or continue ART
3. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read and explained to them by a member of the study staff and they can give informed consent by using their thumb print
4. Availability for follow-up for the planned study duration

Exclusion Criteria:

1\. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.

Where it's running

• Institute of HIV Research and Innovation
  Bangkok, Thailand Recruiting

Study contacts

• Principal investigator: Somchai Sriplienchan, MD, MPH — SEARCH Research Foundation
• Study coordinator: Nitiya Chomchey, RN, PhD
• Email: nitiya.c@searchthailand.org
• Phone: 66 82 899 4433

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining immune-enhancing antibodies and vaccines to control HIV after early infection

  This test will see if giving long-acting HIV antibodies together with therapeutic vaccines helps people who began ART during acute HIV infection control viral levels after a planned treatment interruption.

  Recruiting Phase 1 Henry M. Jackson Foundation for the Advancement of Military Medicine · Pathum Wan, Bangkok · NCT06484335

• Cohort study on acute HIV infection and treatment outcomes

  This study is testing how starting HIV treatment right after diagnosis affects the chances of long-term remission in patients and what factors might help achieve that.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT05728996

• Combination broadly neutralizing HIV antibodies given with ART during acute infection to try to induce remission

  This trial will try giving two HIV-specific broadly neutralizing antibodies along with starting ART to ART-naïve adults with acute HIV infection to see if it delays viral rebound and reduces the viral reservoir.

  Recruiting at 11 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 11 other locations · NCT05719441

• Characterizing acute HIV infection in high-risk individuals

  This study is trying to learn more about people with early HIV infection by looking at their health, behavior, and immune responses to help improve future treatments and vaccines.

  Recruiting SEARCH Research Foundation · Bangkok, Bangkok · NCT00796146

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.